INNOVENT BIO (01801) Completes Global Strategic Collaboration with Takeda Pharmaceutical and Issues 6.9138 Million Shares Under General Mandate

Stock News12-05

INNOVENT BIO (01801) announced the completion of its global strategic collaboration with Takeda Pharmaceutical Co Ltd (through its wholly-owned subsidiary Takeda Pharmaceuticals International AG). All conditions precedent under the licensing, option, and cooperation agreement, as well as the share issuance agreement, have been fulfilled or waived (where applicable). Consequently, the licensing agreement has been completed, and the share issuance was finalized on December 4, 2025. Following the completion, the company allotted and issued 6.9138 million shares to the subscriber, representing approximately 0.40% of its total issued share capital post-issuance. The gross proceeds from the share issuance amounted to approximately HKD 778 million (based on a subscription price of HKD 112.56 per share), with net proceeds of around HKD 777 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment